This is a Phase I study in HLA-A*02 and HLA-A*03 patients with survivin-positive malignant gliomas. It is designed to test the safety and tolerability of a cancer vaccine regimen consisting of the peptide conjugate SVN53-67/M57-KLH in Montanide.
Objectives: To determine the toxicity profile of the SVN53-67/M57-KLH peptide in Montanide ISA 51 plus with GM-CSF in patients with malignant glioma. To measure the immune responses induced by SVN53-67/M57-KLH with Montanide ISA 51 plus GM-CSF. To collect preliminary data on therapeutic efficacy of this combination against malignant glioma.